{"id":1403,"date":"2014-04-01T12:01:00","date_gmt":"2014-04-01T10:01:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2014\/riociguat-zur-behandlung-der-pulmonalen-arteriellen-hypertonie"},"modified":"2022-03-17T14:12:55","modified_gmt":"2022-03-17T13:12:55","slug":"riociguat-zur-behandlung-der-pulmonalen-arteriellen-hypertonie","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2014\/riociguat-zur-behandlung-der-pulmonalen-arteriellen-hypertonie","title":{"rendered":"Riociguat zur Behandlung der pulmonalen arteriellen Hypertonie"},"content":{"rendered":"<p>Riociguat (Adempas\u00ae) ist ein neues, oral einzunehmendes Arzneimittel zur Behandlung der pulmonalen arteriellen Hypertonie (PAH). Es wurde von der Bayer Pharma AG entwickelt. Der Wirkstoff war bisher nur in USA zugelassen, hat aber am 31.3.2014 auch von der Europ\u00e4ischen Arzneimittel-Agentur (EMA) die Marktzulassung erhalten und zwar zur Behandlung der PAH \u2013 als Monotherapie oder in [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Riociguat (Adempas\u00ae) ist ein neues, oral einzunehmendes Arzneimittel zur Behandlung der pulmonalen arteriellen Hypertonie (PAH). Es wurde von der Bayer Pharma AG entwickelt. Der Wirkstoff war bisher nur in USA zugelassen, hat aber am 31.3.2014 auch von der Europ\u00e4ischen Arzneimittel-Agentur (EMA) die Marktzulassung erhalten und zwar zur Behandlung der PAH \u2013 als Monotherapie oder in [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1520,3365,3366,1832,3369,3368,3367,514,2750,1827,3036,3364,2304],"class_list":["post-1403","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-aflibercept","tag-chest-1-sudie","tag-chest-2-sudie","tag-cor-pulmonale","tag-guanylat-zyklase-hemmer","tag-guanylatzyklase-hemmer","tag-patent-1-studie","tag-pulmonale-hypertonie","tag-radium-223-dichlorid","tag-rechtsherzinsuffizienz","tag-regorafenib","tag-riociguat","tag-rivaroxaban"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1403","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1403"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1403\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1403"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1403"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1403"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}